|
KR100833371B1
(ko)
|
2001-04-27 |
2008-05-28 |
젠야쿠코교가부시키가이샤 |
헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제
|
|
KR101046015B1
(ko)
*
|
2002-10-25 |
2011-07-01 |
젠야쿠코교가부시키가이샤 |
헤테로고리 화합물 및 이것을 유효성분으로 하는 항종양제
|
|
KR101130913B1
(ko)
*
|
2004-03-31 |
2012-03-28 |
젠야쿠코교가부시키가이샤 |
헤테로시클릭 화합물 및 이를 활성 성분으로서 포함하는항악성종양제
|
|
SI1864665T1
(sl)
|
2005-03-11 |
2012-09-28 |
Zenyaku Kogyo Kk |
Imunosupresivno sredstvo, ki obsega heterociklično spojino kot učinkovino
|
|
BRPI0613501A2
(pt)
|
2005-07-01 |
2011-01-11 |
Irm Llc |
composto, composição farmacêutica e uso do mesmo
|
|
RU2415853C2
(ru)
|
2005-07-26 |
2011-04-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Бензимидазолы, применимые в качестве ингибиторов протеинкиназ
|
|
US20070244110A1
(en)
*
|
2006-04-14 |
2007-10-18 |
Zenyaku Kogyo Kabushiki Kaisha |
Treatment of prostate cancer, melanoma or hepatic cancer
|
|
EP2057147A1
(de)
*
|
2006-09-14 |
2009-05-13 |
Astra Zeneca AB |
Pyrimidin-derivate
|
|
WO2008032077A1
(en)
*
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
CN101563339A
(zh)
*
|
2006-09-14 |
2009-10-21 |
阿斯利康(瑞典)有限公司 |
作为 p i 3 k和 m t o r抑制剂用于治疗增殖性疾病的 2 -苯并咪唑基 - 6 -吗啉代 - 4 - (氮杂环丁烷、吡咯烷、哌啶或氮杂)嘧啶衍生物
|
|
WO2008032027A1
(en)
*
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
WO2008032091A1
(en)
*
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
CN101563340A
(zh)
*
|
2006-09-14 |
2009-10-21 |
阿斯利康(瑞典)有限公司 |
用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物
|
|
WO2008032036A1
(en)
*
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
EP2218718A1
(de)
|
2007-11-22 |
2010-08-18 |
Zenyaku Kogyo Kabushikikaisha |
Amorphe form einer heterocyclischen verbindung, feste dispersion und medizinische zubereitung damit sowie verfahren zu ihrer herstellung
|
|
WO2009120094A2
(en)
*
|
2008-03-27 |
2009-10-01 |
Auckland Uniservices Limited |
Substituted pyrimidines and triazines and their use in cancer therapy
|
|
MY155653A
(en)
|
2008-05-23 |
2015-11-13 |
Wyeth Llc |
Triazine compounds as p13 kinase and mtor inhibitors
|
|
US10022381B2
(en)
|
2008-05-23 |
2018-07-17 |
Pfizer Inc. |
Triazine compounds as PI3 kinase and mTOR inhibitors
|
|
TWI378933B
(en)
*
|
2008-10-14 |
2012-12-11 |
Daiichi Sankyo Co Ltd |
Morpholinopurine derivatives
|
|
GB2465405A
(en)
*
|
2008-11-10 |
2010-05-19 |
Univ Basel |
Triazine, pyrimidine and pyridine analogues and their use in therapy
|
|
HUP0800768A2
(en)
|
2008-12-18 |
2012-08-28 |
Bioblocks Magyarorszag Gyogyszerkemiai Es Fejlesztoe Kft |
1,3-heterocycles condensed with monoterpene skeleton, their use and pharmaceutical compositions comprising such compounds
|
|
EP2397479A4
(de)
|
2009-02-12 |
2012-08-01 |
Astellas Pharma Inc |
Heteroringderivat
|
|
CA2756067A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
|
CA2767008C
(en)
|
2009-07-07 |
2018-01-30 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
GB201004200D0
(en)
|
2010-03-15 |
2010-04-28 |
Univ Basel |
Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
|
|
GB201007227D0
(en)
|
2010-04-30 |
2010-06-16 |
Univ Basel |
Piperazinotriazines
|
|
ES2570177T3
(es)
*
|
2010-08-10 |
2016-05-17 |
Astellas Pharma Inc |
Compuesto heterocíclico
|
|
WO2012044641A1
(en)
*
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
CN107501241B
(zh)
|
2011-03-28 |
2020-10-13 |
梅制药公司 |
化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
|
|
WO2013047411A1
(ja)
*
|
2011-09-29 |
2013-04-04 |
富士フイルム株式会社 |
新規なトリアジン誘導体、紫外線吸収剤
|
|
ES2661510T3
(es)
|
2011-12-15 |
2018-04-02 |
Novartis Ag |
Uso de inhibidores de la actividad o función de PI3K
|
|
WO2014055647A1
(en)
*
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
|
US9340540B2
(en)
|
2014-02-28 |
2016-05-17 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
|
CN117164657A
(zh)
|
2014-08-12 |
2023-12-05 |
莫纳什大学 |
定向淋巴的前药
|
|
NZ731185A
(en)
|
2014-10-29 |
2024-03-22 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for mt1-mmp
|
|
MA40933A
(fr)
|
2014-11-11 |
2017-09-19 |
Piqur Therapeutics Ag |
Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
|
|
WO2016138352A1
(en)
|
2015-02-27 |
2016-09-01 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
EP4327809A3
(de)
|
2015-09-02 |
2024-04-17 |
Takeda Pharmaceutical Company Limited |
Tyk2-inhibitoren und verwendungen davon
|
|
CN118063537A
(zh)
|
2015-09-08 |
2024-05-24 |
莫纳什大学 |
定向淋巴的前药
|
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
CN105175410B
(zh)
*
|
2015-10-14 |
2018-01-05 |
湖南华腾制药有限公司 |
三嗪类化合物及其制备方法和抗肿瘤应用
|
|
MX389001B
(es)
|
2015-10-23 |
2025-03-20 |
Navitor Pharm Inc |
Moduladores de interacción de sestrina-gator2 y sus usos.
|
|
WO2017106352A1
(en)
|
2015-12-14 |
2017-06-22 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of mthfd2 and uses thereof
|
|
CN109069486A
(zh)
|
2015-12-14 |
2018-12-21 |
X4 制药有限公司 |
治疗癌症的方法
|
|
PT3426243T
(pt)
|
2016-03-09 |
2021-08-19 |
Raze Therapeutics Inc |
Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos
|
|
EP4234552A3
(de)
|
2016-03-09 |
2023-10-18 |
Raze Therapeutics, Inc. |
3-phosphoglycerat-dehydrogenase-inhibitoren und verwendungen davon
|
|
US11337969B2
(en)
|
2016-04-08 |
2022-05-24 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
JP6994767B2
(ja)
|
2016-06-21 |
2022-01-14 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
Cxcr4阻害剤およびその使用
|
|
EP3808748B1
(de)
|
2016-06-21 |
2026-05-20 |
X4 Pharmaceuticals, Inc. |
Substituierte piperidine als cxcr4-inhibitoren
|
|
US10988465B2
(en)
|
2016-06-21 |
2021-04-27 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
|
TW201815787A
(zh)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TWI763722B
(zh)
|
2016-10-14 |
2022-05-11 |
美商林伯士拉克許米公司 |
Tyk2抑制劑及其用途
|
|
CN110300590A
(zh)
|
2016-10-21 |
2019-10-01 |
林伯士拉克许米公司 |
Tyk2抑制剂及其用途
|
|
EP3538091A4
(de)
|
2016-11-08 |
2020-06-10 |
Navitor Pharmaceuticals, Inc. |
Phenyl-amino-piperidin-mtorc-inhibitoren und verwendungen davon
|
|
US20180193270A1
(en)
|
2016-11-29 |
2018-07-12 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
|
EP3559018A1
(de)
|
2016-12-23 |
2019-10-30 |
Bicyclerd Limited |
Peptidderivate mit neuartigen verbindungsstrukturen
|
|
ES2985986T3
(es)
|
2017-01-06 |
2024-11-08 |
Bicyclerd Ltd |
Conjugado biciclo para tratar el cáncer
|
|
JPWO2018131659A1
(ja)
*
|
2017-01-11 |
2019-12-12 |
国立研究開発法人国立がん研究センター |
免疫療法剤
|
|
AU2018230737B2
(en)
|
2017-03-08 |
2022-09-22 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors, uses, and methods for production thereof
|
|
EP3375778A1
(de)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidinderivate
|
|
EP3375784A1
(de)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridonderivate
|
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
|
ES3040534T3
(en)
|
2017-04-26 |
2025-11-03 |
Navitor Pharm Inc |
Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
|
|
EP3615550A1
(de)
|
2017-04-27 |
2020-03-04 |
BicycleTx Limited |
Bicyclische peptidliganden und ihre verwendungen
|
|
EP3630118A4
(de)
|
2017-05-23 |
2021-03-31 |
MEI Pharma, Inc. |
Kombinationstherapie
|
|
WO2019002842A1
(en)
|
2017-06-26 |
2019-01-03 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
|
|
IL317854A
(en)
|
2017-07-28 |
2025-02-01 |
Takeda Pharmaceuticals Co |
TYK2 inhibitors and their uses
|
|
JP7670481B2
(ja)
|
2017-08-04 |
2025-04-30 |
バイスクルテクス・リミテッド |
Cd137に対して特異的な二環式ペプチドリガンド
|
|
WO2019034868A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
|
|
MX2020001727A
(es)
|
2017-08-14 |
2020-03-20 |
Mei Pharma Inc |
Terapia de combinacion.
|
|
WO2019034866A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
|
|
EP4306524A3
(de)
|
2017-08-29 |
2024-09-11 |
PureTech LYT, Inc. |
An das lymphatische system gerichtete lipidprodrugs
|
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
EP3727362A4
(de)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
Lipidprodrugs von mycophenolsäure und ihre verwendungen
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
EP3737666A4
(de)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Proteinabbaumittel und verwendungen davon
|
|
CA3089762A1
(en)
|
2018-01-29 |
2019-08-01 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
|
AU2019212969B2
(en)
|
2018-01-29 |
2025-01-23 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
|
CA3091775A1
(en)
|
2018-02-23 |
2019-08-29 |
Bicycletx Limited |
Multimeric bicyclic peptide ligands
|
|
KR20260028873A
(ko)
|
2018-02-27 |
2026-03-04 |
아텍스 바이오파마 인코포레이티드 |
Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체
|
|
IL301501B2
(en)
|
2018-04-24 |
2024-10-01 |
Vertex Pharma |
Antiproliferation compounds and uses thereof
|
|
EP3784669B1
(de)
|
2018-04-24 |
2023-10-25 |
Vertex Pharmaceuticals Incorporated |
Pteridinonverbindungen und verwendungen davon
|
|
US10980784B2
(en)
|
2018-06-15 |
2021-04-20 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
US12454520B2
(en)
|
2018-07-06 |
2025-10-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
|
EP3846793B1
(de)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e-inhibitoren und verwendungen davon
|
|
JP7619951B2
(ja)
|
2018-10-15 |
2025-01-22 |
武田薬品工業株式会社 |
Tyk2阻害剤およびその使用
|
|
WO2020084305A1
(en)
|
2018-10-23 |
2020-04-30 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
WO2020086816A1
(en)
|
2018-10-24 |
2020-04-30 |
Navitor Pharmaceuticals, Inc. |
Polymorphic compounds and uses thereof
|
|
WO2020112937A1
(en)
|
2018-11-30 |
2020-06-04 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
EP3670659A1
(de)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarker und verwendungen bei der behandlung von viralen infektionen, entzündlichen oder krebserkrankungen
|
|
EP3897849A1
(de)
|
2018-12-21 |
2021-10-27 |
BicycleTx Limited |
Für pd-l1 spezifische bicyclische peptidliganden
|
|
WO2020128527A1
(en)
|
2018-12-21 |
2020-06-25 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
CA3126034A1
(en)
|
2019-01-23 |
2020-07-30 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
|
US20220184222A1
(en)
|
2019-04-02 |
2022-06-16 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
|
KR102980990B1
(ko)
|
2019-04-05 |
2026-06-25 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Stat 분해제 및 이의 용도
|
|
US11458149B1
(en)
|
2019-05-31 |
2022-10-04 |
Ikena Oncology, Inc. |
TEAD inhibitors and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
US12624044B2
(en)
|
2019-06-10 |
2026-05-12 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US12558427B2
(en)
|
2019-07-17 |
2026-02-24 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
CA3150492A1
(en)
|
2019-09-11 |
2021-03-18 |
Donna L. Romero |
Usp30 inhibitors and uses thereof
|
|
US12215105B2
(en)
|
2019-09-13 |
2025-02-04 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
AU2020376950B2
(en)
|
2019-11-01 |
2026-06-11 |
Supernus Pharmaceuticals, Inc. |
Methods of treatment using an mTORC1 modulator
|
|
EP4069223A4
(de)
|
2019-12-05 |
2023-12-20 |
Janssen Pharmaceutica NV |
Rapamycinanaloga und verwendungen davon
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
CA3161878A1
(en)
|
2019-12-17 |
2021-06-24 |
Matthew M. Weiss |
Irak degraders and uses thereof
|
|
EP4076524A4
(de)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
Irak-degrader und verwendungen davon
|
|
WO2021133917A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca inhibitors and uses thereof
|
|
US11679109B2
(en)
|
2019-12-23 |
2023-06-20 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
JP7810970B2
(ja)
|
2020-02-05 |
2026-02-04 |
シーポート・セラピューティクス・インコーポレイテッド |
神経ステロイドの脂質プロドラッグ
|
|
AR121506A1
(es)
|
2020-03-03 |
2022-06-08 |
Pic Therapeutics Inc |
Inhibidores del eif4e y sus usos
|
|
WO2021188948A1
(en)
|
2020-03-19 |
2021-09-23 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
EP4161521A4
(de)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
Deuterierte irak-abbauer und verwendungen davon
|
|
CN116348476A
(zh)
|
2020-08-03 |
2023-06-27 |
拜斯科技术开发有限公司 |
基于肽的接头
|
|
WO2022038158A1
(en)
|
2020-08-17 |
2022-02-24 |
Bicycletx Limited |
Bicycle conjugates specific for nectin-4 and uses thereof
|
|
EP4232425A4
(de)
|
2020-10-23 |
2024-07-24 |
Nimbus Clotho, Inc. |
Ctps1-inhibitoren und verwendungen davon
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4255895A1
(de)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead-hemmer und verwendungen davon
|
|
US12606568B2
(en)
|
2020-12-09 |
2026-04-21 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
AR124547A1
(es)
|
2020-12-30 |
2023-04-05 |
Kymera Therapeutics Inc |
Degradadores de irak y sus usos
|
|
JP2024506858A
(ja)
|
2021-02-02 |
2024-02-15 |
リミナル・バイオサイエンシーズ・リミテッド |
Gpr84アンタゴニストおよびその使用
|
|
KR20230153387A
(ko)
|
2021-02-02 |
2023-11-06 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
|
WO2022174253A1
(en)
|
2021-02-12 |
2022-08-18 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
MX2023009178A
(es)
|
2021-02-15 |
2023-08-21 |
Kymera Therapeutics Inc |
Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
CN117295737A
(zh)
|
2021-03-05 |
2023-12-26 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
US12325697B2
(en)
|
2021-04-09 |
2025-06-10 |
Nimbus Clio, Inc. |
CBL-B modulators and uses thereof
|
|
AU2022258968A1
(en)
|
2021-04-16 |
2023-10-19 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
CA3217792A1
(en)
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc |
Cdk2 degraders and uses thereof
|
|
US12157732B2
(en)
|
2021-08-25 |
2024-12-03 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
IL310924A
(en)
|
2021-08-25 |
2024-04-01 |
Pic Therapeutics Inc |
Eif4e inhibitors and uses thereof
|
|
JP2024540080A
(ja)
|
2021-10-29 |
2024-10-31 |
カイメラ セラピューティクス, インコーポレイテッド |
Irak4分解剤およびその合成
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4472967A4
(de)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Irak-abbauer und verwendungen davon
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
CN119768393A
(zh)
|
2022-05-25 |
2025-04-04 |
医肯纳肿瘤学公司 |
Mek抑制剂和其用途
|
|
EP4565568A1
(de)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Heteroarylcarboxamid- und verwandte gpr84-antagonisten und verwendungen davon
|
|
EP4565569A1
(de)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Aryl-triazolyl- und verwandte gpr84-antagonisten und verwendungen davon
|
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
US20250059164A1
(en)
|
2023-06-23 |
2025-02-20 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP4780462A1
(de)
|
2023-09-21 |
2026-07-29 |
Takeda Pharmaceutical Company Limited |
Tyk2-inhibitoren zur verwendung bei der behandlung von entzündlicher darmerkrankung
|